Work

Concise Drug Review: Azacitidine and Decitabine

Year: 2013

Type: article

Abstract: The introduction of the hypomethylating agents azacitidine and decitabine has been a major advancement in the treatment of patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia who are ineligible for more intensive treatments. This concise drug review summarizes the current state of treatment with azacitidine and decitabine.

Source: The Oncologist

DOI: 10.1634/theoncologist.2012-0465

Authors: Ellen J.B. Derissen, Jos H. Beijnen, Jan H.M. Schellens

Institutions: Slotervaartziekenhuis, The Netherlands Cancer Institute, Utrecht University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2127289529